plication No.: <u>09/269, 250</u>

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES EVED

Applicant must file the items indicated below within the time period set the Office which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other:
Applicant Must Provide:
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
An initial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For questions regarding compliance to these requirements, please contact:
For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 PatentIn Software Program Support
Technical Assistance703-287-0200 To Purchase Patentin Software703-306-2600
PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY



Dkt. 2799/58994/RDK/ECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

NOV 07 2000

Applicant

Elsa Goulmy

U.S. Serial No.:

09/269,250

Examiner: J. Sour ECE

Filed

May 21, 1999

Art Unit: 1655

NON 73 SUDG

For

METHOD

FOR

TYPING O

OF MIN

MINCENTER 160012900

HISTOCOMPATIBILITY ANTIGEN HA-1

1185 Avenue of the Americas New York, New York 10036

November 1, 2000

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

COMMUNICATION IN RESPONSE TO
OCTOBER 3, 2000 NOTICE TO COMPLY WITH
REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES UNDER 37 C.F.R. §1.821(a)(1) AND (a)(2)

This Communication is submitted in response to a Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures Under 37 C.F.R. §1.821 (a)(1) and (a)(2)issued in connection with the above-identified patent application on October 3, 2000. A copy of this Notice is attached hereto as **Exhibit A**. In accordance with the Notice, the deadline for submitting a response is November 3, 2000. Accordingly, this Communication is being timely filed.

Applicant attaches hereto a paper copy of a Sequence Listing as **Exhibit B** in compliance with the requirements of 37 C.F.R. §1.821. In addition, applicant submits herewith a computer readable copy of the Sequence Listing on the enclosed computer

Applicant: Elsa Goulmy

U.S. Serial No.: 09/269,250 Filing Date: May 21, 1999

Page 2

diskette, which has the same content as the paper copy attached as Exhibit B. Applicant submits as Exhibit C, a Statement in accordance with 37 C.F.R. §1.821(f) certifying that the computer readable form containing the nucleic acid and/or amino acid sequences required by 37 C.F.R. §1.821(f) and submitted in connection with the above-identified application, has the same information which is submitted herewith as Exhibit B entitled "Sequence Listing".

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorneys invite the Examiner to telephone at the number provided below.

Applicant: Elsa Goulmy

U.S. Serial No.: 09/269,250 Filing Date: May 21, 1999

Page 3

No fee is deemed necessary in connection with the filing of this Communication. If any additional fees are required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Assistant Commissioner for Patents Washington, D.C. 20231

Robert D. Katz

Reg. No. 30,141 Jane M. Love

Reg. No. 42,812

Robert D. Katz

Registration No. 30,141

Jane M. Love

Registration No. 42,812

Attorneys for Applicants

Cooper & Dunham LLP

1185 Avenue of the Americas

New York, New York 10036

(212) 278-0400